

EUnetCCC symposium **Innovating Cancer Care Through De-escalation Studies**

5-6 March 2026
The Netherlands Cancer Institute, Amsterdam

We are pleased to invite you to the first symposium hosted by the EU funded Joint Action EUnetCCC in collaboration with the European Academy of Cancer Sciences.

De-escalation studies aim to reduce treatment intensity while maintaining the effectiveness of cancer therapies. The overarching goal is to improve patients' quality of life during and after treatment by minimizing side effects, toxicity, and late effects.

This symposium will explore the key challenges and essential steps required to successfully launch and complete de-escalation trials. Our aim is to identify best practices by fostering interdisciplinary collaboration, ultimately making high-quality de-escalation trials accessible to a growing number of patients.

Target audience: We will host up to 200 participants including clinicians, researchers, policy makers, bioinformaticians, healthcare professionals, patient representatives and key industry stakeholders relevant for de-escalation studies.

Key highlights:

- The current paradigms in cancer de-escalation trials
- How to tell patients that less can be more in cancer care?
- Biomarkers enabling treatment reduction
- Immunotherapy – can we stop early?
- How to realize de-escalation trials?

Registration opens: 1 December 2025


Registration closes: 1 February 2026

Format: On-site only, first-come, first-served.

Registration Fee: Free of charge.

Travel & Accommodation: Participants are responsible for their own travel and accommodation expenses.

Symposium "Innovating Cancer Care Through De-escalation Studies"



QR code for website and registration

Sincerely - Symposium Organising Committee